The McCullough Protocol: Base Spike Detoxification

A Clinician’s Guide to Nattokinase, Bromelain, and Curcumin for Post-COVID and Post-Vaccine Recovery

Author: Yoon Hang “John” Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine MD Osher Fellow - U of Arizona Integrative Medicine Fellowship | IFM Scholarship Recipient

Physician - Direct Integrative Care — www.directintegrativecare.com

Published: March 2026

Introduction

One of the most persistent clinical challenges following the COVID-19 pandemic has been the management of post-acute sequelae of SARS-CoV-2 infection (PASC)—commonly known as long COVID—and, in some patients, post-vaccination syndromes. A growing body of mechanistic research has identified the SARS-CoV-2 spike protein as a central mediator of endothelial damage, microthrombosis, and chronic inflammation in both conditions.^1,2

In 2023, cardiologist Peter A. McCullough, MD, and colleagues published the first formal rationale for what they termed the McCullough Protocol: Base Spike Detoxification (BSD)—a triple-agent nutraceutical regimen composed of nattokinase, bromelain, and curcumin designed to target persistent spike protein through enzymatic degradation, anti-inflammatory modulation, and microclot dissolution.^1,3

This article reviews the scientific basis, proposed mechanisms, dosing parameters, safety considerations, and current evidence limitations of the McCullough BSD protocol from an integrative medicine perspective. As with all emerging interventions discussed on this site, this represents a synthesis of available data—not a treatment endorsement—and should inform, rather than replace, individualized clinical decision-making.

Background: Spike Protein Persistence and Pathology

Detection studies have identified circulating or tissue-resident spike protein for 6–15 months after COVID-19 infection and for at least 2–4 months following mRNA vaccination in a subset of individuals with post-acute symptoms.^1,2 Spike protein has been found in the brain, heart, liver, kidneys, ovaries, and testes at autopsy, and within thrombus material in cases of vaccine-associated thrombotic injury.³

The pathogenic role of the spike protein is mediated through several pathways: direct endothelial injury via ACE2 receptor engagement, activation of the NF-κB inflammatory cascade, NLRP3 inflammasome priming, and promotion of fibrin-rich microclot formation that resists normal fibrinolysis.^1,2,4 These overlapping mechanisms create the clinical picture seen in many long COVID patients: fatigue, exercise intolerance, brain fog, dysautonomia, and vascular complications.

The McCullough Base Spike Detoxification Protocol

The BSD protocol centers on three over-the-counter agents chosen for their complementary mechanisms of action: proteolytic degradation of spike protein, anti-inflammatory signaling, dissolution of fibrin-rich microthrombi, and mild anticoagulation.¹

1. Nattokinase

Nattokinase is a fibrinolytic serine protease derived from Bacillus subtilis var. natto, the organism responsible for the traditional Japanese fermented soybean food natto. Tanikawa et al. (2022) demonstrated that nattokinase degrades SARS-CoV-2 spike protein on cell surfaces in a dose- and time-dependent manner in vitro.⁵ Separate in vitro work has shown that nattokinase can degrade fibrinolysis-resistant “fibrinaloid” microclots of the type associated with long COVID.⁶

Proposed mechanisms: Direct proteolysis of spike protein; fibrin degradation and microclot dissolution; mild antithrombotic and antihypertensive effects.

Protocol dosing: 2,000 FU (approximately 100 mg) orally twice daily, taken on an empty stomach. Starting doses may be titrated upward based on clinical response.^1,3

2. Bromelain

Bromelain is a cysteine protease complex isolated from pineapple stem (Ananas comosus). Sagar et al. (2021) demonstrated that bromelain diminishes expression of ACE-2 and TMPRSS2 in VeroE6 cells, cleaves the SARS-CoV-2 spike ectodomain, and significantly reduces viral infection in cell culture.⁷ Bromelain also exerts anti-inflammatory effects through modulation of prostaglandin and thromboxane pathways and has established fibrinolytic and antiplatelet activity.^2,7

Proposed mechanisms: Proteolytic degradation of spike protein; inhibition of spike–ACE2 binding; NF-κB suppression; fibrinolytic and antiplatelet support.

Protocol dosing: 500 mg orally once daily on an empty stomach.^1,3

3. Curcumin

Curcumin is the principal polyphenol in turmeric (Curcuma longa). It is one of the most extensively studied natural anti-inflammatory compounds, with well-characterized inhibitory effects on NF-κB signaling and NLRP3 inflammasome activation—two pathways directly implicated in spike protein–mediated inflammation.^8,9 Nanocurcumin has been shown to suppress spike-stimulated expression of IL-6, IL-1β, and IL-18 and to reduce NLRP3 inflammasome machinery proteins in lung epithelial cells.¹⁰

Proposed mechanisms: NF-κB and NLRP3 inflammasome inhibition; antioxidant and endothelial-protective effects; possible interference with spike–ACE2 binding; synergy with bromelain on anti-inflammatory pathways.

Protocol dosing: 500 mg orally twice daily in nano, liposomal, or piperine-enhanced formulation for adequate bioavailability.^1,3

Summary of Putative Mechanisms

The McCullough BSD protocol is proposed to provide four primary mechanisms of action:¹

Relation to Broader Long-COVID Care

The BSD protocol is best understood as one adjunctive layer within a comprehensive long-COVID management strategy—not a standalone cure. Independent reviews of spike-related pathology have identified overlapping and complementary approaches that include:^2,4

• Autophagy induction through time-restricted eating, intermittent fasting, and caloric/protein restriction to enhance cellular clearance of damaged proteins.
• Foundational micronutrient support (vitamin D, vitamin C, zinc, selenium) for immunomodulation and oxidative stress control.
• Anti-inflammatory dietary patterns, cruciferous vegetables for phase II hepatic detoxification support, and adequate hydration.
• Sleep optimization, autonomic nervous system rehabilitation, graded physical activity, and gut microbiome restoration.
• Individualized pharmaceutical interventions as indicated: low-dose naltrexone for neuroinflammation, hydroxychloroquine for autoimmune features, colchicine for pleurodynia, or anticoagulation for documented thrombotic risk.

The BSD protocol provides enzymatic and polyphenolic support on top of these foundational lifestyle and micronutrient strategies.⁴

Current Evidence and Limitations

Transparency about the evidence base is essential. The McCullough BSD protocol is supported by mechanistic reasoning, in vitro data, case experience, and theoretical integration—not by large-scale randomized controlled trials (RCTs) in human long-COVID or vaccine-injury populations.^1,3

Specifically:

• Nattokinase’s spike protein degradation has been demonstrated only in cell culture models; no human pharmacokinetic or pharmacodynamic studies have confirmed that oral nattokinase reaches systemic concentrations sufficient to cleave spike protein in vivo.
• Bromelain’s inhibition of ACE-2, TMPRSS2, and spike protein has been shown in VeroE6 and Calu-3 cell lines but not in clinical trials for post-COVID syndromes.
• Curcumin’s NF-κB and NLRP3 modulation is well established in preclinical models, but its notoriously poor oral bioavailability limits direct extrapolation to clinical efficacy without enhanced formulations.
• A 2023 narrative review by Halma et al. cataloged numerous candidate treatments for spike-related pathology (vitamins, flavonoids, anticoagulants, immunomodulators) but emphasized that high-quality clinical evidence remains limited for most interventions.
• The original McCullough protocol publication itself acknowledges that no therapeutic claims can be made and that large-scale, prospective, randomized, double-blind, placebo-controlled trials are warranted.

Academic commentators at McGill University’s Office for Science and Society have explicitly criticized the marketing of nattokinase-based “spike detox” products as premature and potentially misleading, underscoring the gap between laboratory findings and clinical validation.¹¹

Safety Considerations and Clinical Precautions

From a functional and integrative medicine standpoint, the following precautions apply:^1,2,11

Bleeding Risk

Both nattokinase and bromelain have fibrinolytic and anticoagulant properties. Use caution or avoid in patients on warfarin, direct oral anticoagulants (DOACs), dual antiplatelet therapy, or those with thrombocytopenia, recent surgery, active bleeding, or known coagulopathies. If used alongside anticoagulants, close monitoring of bleeding parameters is essential.

Drug–Nutrient Interactions

Bromelain can increase absorption of certain medications (particularly antibiotics such as amoxicillin and tetracycline). Curcumin modulates CYP3A4 and CYP2C9 enzymes and may alter the metabolism of drugs processed through these pathways. Curcumin also has additive antiplatelet effects.

Organ Function

Dose adjustments or closer monitoring may be warranted in patients with significant hepatic or renal dysfunction.

Special Populations

Data in pregnancy, breastfeeding, and pediatric populations are sparse for high-dose enzyme protocols. Conservative avoidance is generally recommended in these groups.²

Clinical Integration: A Practical Approach

For clinicians considering the BSD protocol as part of an integrative long-COVID care plan, the following framework may be useful:

• Individualized risk stratification: Assess coagulation status, concurrent medications (especially anticoagulants and antiplatelets), platelet counts, autoimmune markers, and mast cell activation status before initiation.
• Slow titration: Consider starting nattokinase at 2,000 FU once daily (rather than twice daily) and bromelain/curcumin at lower doses for the first 1–2 weeks, with symptom tracking.
• Enhanced bioavailability: Use liposomal, nano, or piperine-enhanced curcumin formulations. Standard curcumin powder has bioavailability too low to achieve meaningful anti-inflammatory tissue levels.
• Protocol duration: The original protocol suggests 3–12 months or longer, guided by clinical parameters and symptom trajectory.
• Comprehensive integration: Embed the BSD protocol within a broader treatment plan that includes autonomic rehabilitation, sleep restoration, gut repair, graded movement, dietary optimization, and management of comorbidities.
• Monitoring: Follow symptom scores, inflammatory markers (CRP, ferritin, D-dimer where appropriate), and bleeding symptoms at regular intervals.

Conclusion

The McCullough Base Spike Detoxification protocol represents a mechanistically plausible, nutraceutical-based adjunctive strategy for patients with persistent symptoms attributable to SARS-CoV-2 spike protein. Its three components—nattokinase, bromelain, and curcumin—each bring individual preclinical evidence for spike protein degradation, anti-inflammatory modulation, or microclot resolution.

However, the protocol remains in the category of emerging evidence. No large-scale human RCTs have been completed, and the leap from in vitro spike degradation to clinical symptom resolution has not been bridged by prospective data. Clinicians should present this protocol honestly to patients: as a reasonable, generally well-tolerated option supported by mechanistic rationale and case experience, but not yet validated by the gold standard of clinical evidence.

In my own practice, I position interventions like the BSD protocol within a framework that prioritizes root-cause investigation, individualized risk–benefit assessment, and transparent communication about evidentiary certainty. As Dr. Andrew Weil has taught: marry results, not methods. The results we seek—reduced inflammation, restored vascular integrity, improved quality of life—should always drive our therapeutic choices, informed by the best available evidence at any given time.

References

1. Frumento, R. J., Barham, H. P., Abraham, R. L., Coleman, W. T., III, White, J. R., & McCullough, P. A. (2023). Clinical approach to post-acute sequelae after COVID-19 infection and vaccination. Cureus, 15(11), e49204. https://doi.org/10.7759/cureus.49204
2. Halma, M. T. J., Plothe, C., Marik, P., & Lawrie, T. A. (2023). Strategies for the management of spike protein-related pathology. Microorganisms, 11(5), 1308. https://doi.org/10.3390/microorganisms11051308
3. McCullough, P. A., Wynn, C., & Procter, B. C. (2023). Clinical rationale for SARS-CoV-2 base spike protein detoxification in post COVID-19 and vaccine injury syndromes. Journal of American Physicians and Surgeons, 28(3), 90–93.
4. Halma, M. T. J., Marik, P. E., & Saleeby, Y. M. (2023). Exploring autophagy in treating spike protein-related pathology. Preprints, 202306.1903.
5. Tanikawa, T., Kiba, Y., Yu, J., Hsu, K., Chen, S., Ishii, A., Yokogawa, T., Suzuki, R., Inoue, Y., & Kitamura, M. (2022). Degradative effect of nattokinase on spike protein of SARS-CoV-2. Molecules, 27(17), 5405. https://doi.org/10.3390/molecules27175405
6. Kell, D. B., & Pretorius, E. (2022). Are fibrinaloid microclots a cause of autoimmunity in long COVID and other post-infection diseases? Biochemical Journal, 480(15), 1141–1170. https://doi.org/10.1042/BCJ20230241
7. Sagar, S., Rathinavel, A. K., Lutz, W. E., Struble, L. R., Khurana, S., Schnaubelt, A. T., Mishra, N. K., Guda, C., Palermo, N. Y., Broadhurst, M. J., Hoffmann, T., Bayles, K. W., Reid, S. P. M., Borgstahl, G. E. O., & Radhakrishnan, P. (2021). Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. Clinical and Translational Medicine, 11(2), e281. https://doi.org/10.1002/ctm2.281
8. Rattis, B. A. C., Ramos, S. G., & Celes, M. R. N. (2021). Curcumin as a potential treatment for COVID-19. Frontiers in Pharmacology, 12, 675287. https://doi.org/10.3389/fphar.2021.675287
9. Hasanzadeh, S., Read, M. I., Bland, A. R., Majeed, M., Jamialahmadi, T., & Sahebkar, A. (2020). Curcumin: An inflammasome silencer—a case for inhibiting NLRP3 inflammasome, suppression of inflammation with curcumin. Pharmacological Research, 159, 104921. https://doi.org/10.1016/j.phrs.2020.104921
10. Thongtham, N., Kitisin, T., Wannapaiboon, S., Polpanich, D., Suwattanasophon, C., Choonate, N., Khongkow, M., & Rojsitthisak, P. (2023). Targeting spike glycoprotein S1 mediated by NLRP3 inflammasome machinery and the cytokine releases in A549 lung epithelial cells by nanocurcumin. Pharmaceutics, 15(6), 1707. https://doi.org/10.3390/pharmaceutics15061707
11. Bhagavathula, A. S. (2024). Nattokinase’s clot-busting promises sway scientists who should know better. McGill University Office for Science and Society. https://www.mcgill.ca/oss/article/covid-19-critical-thinking-health-and-nutrition/nattokinases-clot-busting-promises-sway-scientists-who-should-know-better